Mexico: Biotechnology at Third Stage of Development

Last Updated: 17 January 2005
Most Read Contributor in Mexico, November 2018

By Daniel Barrón Pastor

Biotechnology is modifying the cultural and economic relations within societies in the globalized world. Treatments and new drugs, genetically modified foods, materials, biologically controlled production processes, and many other applications, may well become part of our everyday lives improving health, agricultural, industrial, and energy production, affecting our societies as profoundly as oil or information technologies have already done.

Moreover, the knowledge of biological topics is modifying every ideology, language and conscience of humankind. The generation of disciplines such as ecology, sustainable development, biophilosophy, bioeconomy, as well as public discussion about cloning, genetically modified organisms, bioterrorism and the technological fear that involves each subject, show that life sciences are part of a major change in the conscience and perception of societies.

The cultural and economic transformations that arise from the life sciences allow to think about them as a major industrial revolution. Thus, if biotechnology shares the behavior of other industrial revolution phenomena of modern society (automobiles-or internal combustion motors, plastics, computers, etc.), then biotechnology be in a generational cycle that will span over 50 years.1

Until this moment, biotech is showing a development behavior that shares a lot of similarities with other industrial revolution generational cycles: In the first stage, the foundations of research methodologies which change how we study the subject (the biotech cycle could begin in the late 70’s and early 80’s, when we found the recombinant DNA and hybridome technologies, which change how we study biology). The second stage shows a lot of research methodologies but few discoveries that became products. The third stage is marked by a flow of innovative products derived from the new methodologies. In the fourth stage the products became incorporated into daily life, and in the final stage companies and products became fully integrated into the science research and the retail sectors of society.2

It is necessary to point out that the development of each stage is gradual and that the frontiers between them are not marked by a specific kind of event. As well, the appearance of events of a stage does not involve that events of the prior one have ended or that events of other one have appeared. Therefore, we can observe that biotech’s generational cycle is in the midst of the third stage and that there are some signs that involve the second and fourth stage.

The second stage events of the biotech’s generational cycle (a lot of research methodologies but few discoveries that became products) could be observed in the late 80’s and 90’s, specifically in the input of DNA sequences into databases (genes, genomes), the identification of function and participation in the cell and organisms physiology and the appearance of a generation of products evolved from this technologies (e.g. genetically modified crops, antibiotics, hormones etc. produced by modified microorganisms, water purification systems and new therapeutic methods and drugs). At this stage, investments were focused in research and development activities in basic research and the search/discovery of new molecular entities.

The third stage of the biotech’s generational cycle is marked by an increased flow of innovative products. This evolvement will be clearly observed in the increment of patent applications being submitted in the biotech’s category, when compared with prior years. Also, the third stage can be observed in the market wherein a large quantity of new biotechnological products are emerging.

This increased flow of products is not casual. Investors seem to be more risk conscious than in the 90’s decade, because the genomic and proteomic knowledge produced at the 90’s decade is evolving into products and, at the same time, the investors perception about research in these topics is that they need to become the high risk of the investments and a frustration feeling in terms of profits.

In this sense, Roger Longman at the 22nd JP Morgan Healthcare Conference said that "new molecular entity discovery has become so difficult to predict and localize that it may not be sensible to invest at the rates we have in the past" 3. Thus, the risks are higher in terms of the lower probability of discovery and the larger amount of capital needed for research. Also, he states that investment strategies are flowing from the risky research programs to the more secure late stages of product development:

"statistically, the drug industry and financial markets are paying therecognition of value, not new molecular entity discovery".

This change in the investment ideology is causing biotech companies to reorganize, cut back on their research programs and execute a business strategy of in-licensing products that are already in clinical development.

"To maintain anything close to traditional margins, drug developers must learn to explore the entire Research & development value chain for innovation, Longman said ‘the business development function in a company has become as important—if not more so— than the discovery function.’" 4

So, at this third stage of the cycle, the biotech industry is modifying the R&D activities in order to be more attractive to the investors, and the products derived from said new investments are signs of the incoming fourth stage of the biotech’s generational cycle.

Societies have also been modified but changes are less clear than those at industrial modifications. In the second half of the XXth century, the general attitude to life sciences advances was of surprise about knowledge, great expectations about, new medicine, caution about ecology problems, and ignorance translated in technologic fear. Therefore, the biotech industry and the nations have invested a lot of money in education, divulgation and media programs trying to keep the positive attitudes and trying to modify the bad ones. The objectives of these programs could be resumed as 1) keeping surprises that help in the development of the expectations, and 2) attacking ignorance and technologic fear.

Therefore, the impact of education programs in societies has been such way that ideologies, languages and disciplines have more terms and metaphors related to life sciences than ever in history. However, the attitudes of the ???public toward biotech seem to be the predominant until now,only that the public has much more information.

About consumers and public expectations, at this third stage of the biotech industrial revolution, the new drugs and treatments are being well accepted; the public has great expectations about the new medicine that would arise from the advances in the understanding of the human genome gene therapy and stem cells; consumers still have great confusion about ecologic and health risks related to genetically modified food and the new materials and industrial processes are quite known.

From all the above biotech industry wants to develop the local markets by introducing the new products through the public’s daily life needs and publicity, and wants to try –together with the national governments- to improve better local programs of education, divulgation, and research, in order to induce the nations to become societies of consumers (and developers5) of biotechnological products.

The introduction of new products when government and industry invest in local science development, could cause that the local communities tend to be better informed and therefore avoid adverse reactions in the acceptance of local markets caused by technologic fear.

Finally, the third stage of the biotechnology revolution is a complex challenge wherein the industry, the governments and the societies of the globalized world are being modified in order to survive to the biotech century.

Footnotes

1. "This cycles are part of the possible causes of long waves or long cycles of the world economy, also known as Kondratiev cycles. This cycles were known through empiric studies wherein the price tendency statistics, the interest rate and the market. Now, the economic variables related with the long waves are: 1) the technology advance and innovation (Shumpeter, Mensh and Kleinknecht); 2) the capital’s transformation and its impact in the different stages (Mandel and Forrester); 3) the effect of the long waves over the employment (Freeman); 4) the prime matter as a central variable (Rostow); 5) institutional and social modifications (Freeman, Pérez and Dosi). However, the long waves are a difficult to quantify phenomena because, in part, to the inconsistence and amplitude of the disposable statistical series." Paragraph taken from Leonel Corona Treviño, Technology, innovation and economical cycles, in Economical theories of technology, jus, CIECAS and IPN, Mexico 1999; page 130.

2. John F. Wong, Is biotech in the midst of a fifty year cycle? Genetic Engineering News –www.genengnews.com; March 1, 2005, vol 25, no. 5. Referring to interview with Nola Masterson, Ph.D.,. (Science Futures –San Francisco)

3. Roger Longman is the Managing Director of Windhover Information, Inc., and editor of In vivo: The business and Medicine report. Text from Lorraine Ruff and David Gabrilska, 22nd JPMorgan Annual Healthcare Conference Report, There’s is gold in tem that molecular tailings. July 22, 2005. http://www.iowatech.com/jpmorgan/drug_trends_04.htm??p1

4. Roger Longman, Ibidem.

5. Developing research and production systems in developed countries will reduce costs of research, development and production, causing the construction of a strong moral-scientist leadership at reduced costs. Therefore, at this third stage of the biotech industrial revolution, profitable solutions for the industry, investors and societies, will arise when the developing countries do more –—or have more investment— in research and development.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions